J. Pharm. Pharmacogn. Res., vol. 12, suppl. 1, pp. S57-S60, Dec 2024.
DOI: https://doi.org/10.56499/jppres23.1764_12.s1.57
Short Communication
Effect of erythropoietin on cerebral palsy prevention in hypoxic-ischemic encephalopathy. Hemoglobin, C-reactive protein, caspase-3, and tumor necrosing factor-α levels
Fadhilah Tia Nur1,2*, Harsono Salimo2, Hardiono D. Pusponegoro3, Ari Natalia Probandari4, Bambang Purwanto5, Soetrisno6
1Doctoral Program of Medicine, Medical Faculty, Sebelas Maret University, Indonesia.
2Department of Child Health, Medical Faculty, Sebelas Maret University, Indonesia
3Department of Child Health, Medical Faculty, University of Indonesia, Indonesia.
4Department of Public Health, Medical Faculty, Sebelas Maret University, Indonesia.
5Department of Internal Medicine, Medical Faculty, Sebelas Maret University, Indonesia.
6Department of Obstetrics and Gynecology, Medical Faculty, Sebelas Maret University, Indonesia.
*E-mail address: fadhilahtia@staff.uns.ac.id; ORCID: 0009-0008-6184-4318
Abstract
Context: Hypoxic ischemic encephalopathy (HIE) is one of the leading causes of cerebral palsy (CP) and neonatal mortality in developing countries. Erythropoietin (Epo) is one of the newest neuroprotective therapies to prevent cerebral palsy.
Aims: To analyze the effect of Epo as a neuroprotective agent to prevent CP.
Methods: A randomized, double-blind, placebo-controlled trial was conducted between January and October 2022 in the neonatology ward at a tertiary hospital in Surakarta, Indonesia. Twenty-five infants born at 32 weeks or more of gestation with HIE based on Thompson’s criteria were determined to receive Epo or placebo treatments. After their birth, as well as at 2, 3, 4, and 5 days of age, saline placebo or Epo (1000 IU per kilogram of body weight) was administered intravenously within 24 hours. Hemoglobin, c-reactive protein (CRP), caspase-3, and tumor necrosing factor-' (TNF-α) levels were measured both pre- and post-treatment. Neurological examination was performed at 2, 4, and 6 months of age to assess the occurrence of CP.
Results: Hemoglobin and caspase-3 levels displayed an effect of Epo administration, in contrast with no significant difference found on CRP and TNF-a levels after the same treatment. However, the differences in the occurrence of cerebral palsy in the treatment group were statistically insignificant.
Conclusion: Epo has significant neuroprotective effects on caspase-3 levels, but this is not enough to prevent CP.
Keywords: anxiety; cerebral palsy; erythropoietin; hypoxic ischemic encephalopathy.
Paper presented at the 4th International Conference on Medicine and Health Sciences (ICO-Helics), 2023.

Citation Format: Nur FT, Salimo H, Pusponegoro HD, Probandari AN, Purwanto B, Soetrisno (2024) Effect of erythropoietin on cerebral palsy prevention in hypoxic-ischemic encephalopathy. Hemoglobin, C-reactive protein, caspase-3, and tumor necrosing factor-α levels. J Pharm Pharmacogn Res 12(suppl. 1): S57–S60. https://doi.org/10.56499/jppres23.1764_12.s1.57
References
Bax MC, Flodmark O, Tydeman C (2007) Definition and classification of cerebral palsy: From syndrome toward disease. Dev Med Child Neurol Suppl 109: 39–41. https://pubmed.ncbi.nlm.nih.gov/17370481/
Bersani I, Auriti C, Ronchetti MP, Prencipe G, Gazzolo D, Dotta A (2015) Use of early biomarkers in neonatal brain damage and sepsis: state of the art and future perspectives. Biomed Res Int 2015: 253520. https://doi.org/10.1155/2015/253520
Deng C, Li J, Sun F (2019) Effects of hypoxia on caspase-3 expression and neuronal apoptosis in the brain of neonatal mice. Exp Ther Med 17(6): 4517–4521. https://doi.org/10.3892/etm.2019.7487
Diao M, Qu Y, Liu H, Ma Y, Lin X (2019) Effect of carbamylated erythropoietin on neuronal apoptosis in fetal rats during intrauterine hypoxic-ischemic encephalopathy. Biol Res 52(1): 28. https://doi.org/10.1186/s40659-019-0234-7
Graham EM, Burd I, Everett AD, Northington FJ (2016) Blood biomarkers for evaluation of perinatal encephalopathy. Front Pharmacol 13(7): 196. https://doi.org/10.3389/fphar.2016.00196
Horn AR, Swingler GH, Myer L, Linley LL, Raban MS, Joolay Y, Harrison MC, Chandrasekaran M, Rhoda NR, Robertson NJ (2013) Early clinical signs in neonates with hypoxic ischemic encephalopathy predict an abnormal amplitude-integrated electroencephalogram at age 6 hours. BMC Pediatr 13: 52. https://doi.org/10.1186/1471-2431-13-52
Lai MC, Yang SN (2011) Perinatal hypoxic-ischemic encephalopathy. J Biomed Biotechnol 2011: 609813. https://doi.org/10.1155/2011/609813
Massaro AN, Wu YW, Bammler TK, Comstock B, Mathur A, McKinstry RC, Chang T, Mayock DE, Mulkey SB, Van Meurs K, Juul S (2018) Plasma biomarkers of brain injury in neonatal hypoxic-ischemic encephalopathy. J Pediatr 194: 67–75.e1. https://doi.org/10.1016/j.jpeds.2017.10.060
Namusoke H, Nannyonga MM, Ssebunya R, Nakibuuka VK, Mworozi E (2018) Incidence and short term outcomes of neonates with hypoxic ischemic encephalopathy in a peri urban teaching hospital, Uganda: A prospective cohort study. Matern Health Neonatol Perinatol 4: 6. https://doi.org/10.1186/s40748-018-0074-4
Ohlsson A, Aher SM (2020) Early erythropoiesis-stimulating agents in preterm or low birth weight infants. Cochrane Database Syst Rev 2020. https://doi.org/10.1002/14651858.cd004863.pub6
Oorschot DE, Sizemore RJ, Amer AR (2020) Treatment of neonatal hypoxic-ischemic encephalopathy with erythropoietin alone, and erythropoietin combined with hypothermia: History, current status, and future research. Int J Mol Sci 21(4): 1487. https://doi.org/10.3390/ijms21041487
Perrone S, Lembo C, Gironi F, Petrolini C, Catalucci T, Corbo G, Buonocore G, Gitto E, Esposito SMR (2022) Erythropoietin as a neuroprotective drug for newborn infants: ten years after the first use. Antioxidants 11(4): 652. https://doi.org/10.3390/antiox11040652
Simiyu IN, Mchaile DN, Katsongeri K, Philemon RN, Msuya SE (2017) Prevalence, severity and early outcomes of hypoxic ischemic encephalopathy among newborns at a tertiary hospital, in northern Tanzania. BMC Pediatr 17(1): 131. https://doi.org/10.1186/s12887-017-0876-y
Swaiman KF, Wu Y (2017) Cerebral palsy. In: Swaiman KF, Ashwal S, Ferriero DM (eds). Swaiman´s Pediatric Neurology Principles & Practice. Elsevier. Philadelphia, pp. 491–504.
Tataranno ML. Perrone S, Longini M, Buonocore G (2015) New antioxidant drugs for neonatal brain injury. Oxid Med Cell Longev 2015: 108251. https://doi.org/10.1155/2015/108251
Zhao M, Zhu P, Fujino M, Zhuang J, Guo H, Sheikh I, Zhao L, Li XK (2016) Oxidative stress in hypoxic-ischemic encephalopathy: molecular mechanism and therapeutic strategies. Int J Mol Sci 17(12): 2078. https://doi.org/10.3390/ijms17122078
© 2024 Journal of Pharmacy & Pharmacognosy Research